People taking part will receive study tablets over a period of several weeks. During the study, there will be follow-up visits at different times so that changes in tiredness and general well-being can be checked, and safety will also be monitored. Some people will receive modafinil and some will receive placebo, but the treatment is assigned by chance.

The purpose of this study is to evaluate the feasibility and safety of using daratumumab in patients with moderate to severe ME/CFS. The study will involve ten patients who will receive the medication over a period of time. Participants will be monitored for any side effects and changes in their condition. The study aims to gather information on how well patients tolerate the treatment and any potential benefits it may provide.

Throughout the study, researchers will track various aspects of the participants’ health, including physical function, bodily pain, and overall activity levels. This will help determine if daratumumab can be a safe and effective treatment option for those suffering from ME/CFS. The study is expected to continue for a set period, allowing researchers to collect comprehensive data on the medication’s impact on the disease.

The purpose of the study is to evaluate how effective daratumumab is in reducing the symptoms of ME/CFS in patients who have moderate to severe forms of the condition. Participants in the study will receive either daratumumab or a placebo through subcutaneous injections, which means the medication is injected under the skin. The study will last for a period of 26 weeks, during which the participants’ symptoms and overall health will be monitored closely.

Throughout the study, the participants’ progress will be assessed using various measures, including their physical function and daily activity levels. The study aims to provide valuable insights into whether daratumumab can help alleviate the symptoms of ME/CFS and improve the quality of life for those affected by this challenging condition.

The purpose of this study is to determine how well pregabalin and complex rehabilitation help reduce fatigue symptoms in people who have experienced persistent tiredness for at least 6 months after having COVID-19. The study will measure changes in fatigue levels and physical abilities, including how far participants can walk.

During the study, participants will take either pregabalin tablets or placebo tablets. The maximum daily dose of pregabalin will be 300 mg. The study will last for 6 months, during which various aspects of participants’ health will be monitored, including their energy levels, walking ability, quality of life, sleep patterns, and emotional well-being. Regular assessments will be conducted to track participants’ progress throughout the study period.

The purpose of the study is to evaluate the safety and effectiveness of these two medications in reducing fatigue associated with Parkinson’s Disease. Participants will be randomly assigned to receive either Safinamide at a dose of 100 mg per day or Rasagiline at a dose of 1 mg per day. The study will last for 24 weeks, during which time participants will continue their usual Parkinson’s treatment while adding one of these medications. The trial is designed to be double-blind, meaning neither the participants nor the researchers will know which medication each participant is receiving, to ensure unbiased results.

Throughout the study, participants will have regular check-ups to monitor their health and any changes in their symptoms. This will include measuring blood pressure, heart rate, and conducting blood tests. Additionally, participants will be assessed using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale part III (MDS UPDRS-III), which helps evaluate the severity of Parkinson’s symptoms. The study aims to provide valuable information on how these medications can help manage fatigue in people with Parkinson’s Disease.